Neutrophil chemotaxis in granulomatosis with polyangiitis (Wegener's) and idiopathic pulmonary fibrosis
Richter, A. G., Perkins, Gavin D., Chavda, A., Sapey, E., Harper, L. and Thickett, David R.. (2011) Neutrophil chemotaxis in granulomatosis with polyangiitis (Wegener's) and idiopathic pulmonary fibrosis. European Respiratory Journal, Volume 38 (Number 5). pp. 1081-1088. ISSN 0903-1936Full text not available from this repository.
Official URL: http://dx.doi.org/10.1183/09031936.00161910
The presence of antineutrophil cytoplasmic antibodies in granulomatosis with polyangiitis (Wegener's) (GPA) implicates the neutrophil as a key effector cell. Previous studies have reported elevated neutrophil counts in the lung, although the determinants of neutrophil chemotaxis in the GPA lung are unknown. Bronchoalveolar lavage fluid (BALF) cell counts, myeloperoxidase (MPO) and chemokines were measured in 27 patients with GPA, 20 disease controls with idiopathic pulmonary fibrosis (IPF) and six healthy controls. CXC chemokine ligand (CXCL) 8, interleukin (IL)-1 beta, epithelial neutrophil-activating protein 78, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor were measured by ELISA. The neutrophil chemotactic potential of BALF was investigated using the under-agarose method, and specific antibodies were used to examine the role of CXCL8 and IL-1 beta. GPA BALF had an increased neutrophil percentage, and elevated MPO, CXCL8 and G-CSF concentrations compared with healthy controls. Chemotaxis of control neutrophils towards BALF from patients with active (p=0.006) and remission (p=0.077) GPA, and IPF (p=0.001) patients was increased compared with normal controls. BALF-induced chemotaxis correlated with BALF IL-1 beta (r=0.761, p=0.001) and CXCL8 (r=0.640, p=0.012) in GPA, and was inhibited by anti-CXCL8 (85%; p<0.001) and anti-IL-1 beta (69%; p<0.001). Our study confirms a neutrophilia and pro-inflammatory alveolar milieu that persists in clinical remission. CXCL8 and IL-1 beta appear to play important roles in the neutrophil chemotactic response to BALF.
|Item Type:||Journal Article|
|Subjects:||Q Science > QR Microbiology > QR180 Immunology
R Medicine > RC Internal medicine
|Divisions:||Faculty of Medicine > Warwick Medical School|
|Library of Congress Subject Headings (LCSH):||Bronchoalveolar lavage, Chemokines, Interstitial lung diseases, Neutrophils, Wegener's granulomatosis, Vasculitis, Pulmonary fibrosis|
|Journal or Publication Title:||European Respiratory Journal|
|Publisher:||European Respiratory Society|
|Page Range:||pp. 1081-1088|
|Access rights to Published version:||Restricted or Subscription Access|
|References:||1 Gross WL, Csernok E, Flesch BK. ‘‘Classic’’ anti-neutrophil cytoplasmic autoantibodies (cANCA), ‘‘Wegener’s autoantigen’’ and their immunopathogenic role in Wegener’s granulomatosis. J Autoimmun 1993; 6: 171–184. 2 Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87: 4115–4119. 3 Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955–963. 4 Brouwer E, Huitema MG, Mulder AH, et al. Neutrophil activation in vitro and in vivo in Wegener’s granulomatosis. Kidney Int 1994; 45: 1120–1131. 5 Cordier JF, Valeyre D, Guillevin L, et al. Pulmonary Wegener’s granulomatosis. A clinical and imaging study of 77 cases. Chest 1990; 97: 906–912. 6 Schnabel A, Reuter M, Csernok E, et al. Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity. Eur Respir J 1999; 14: 118–124. 7 Newall C, Schinke S, Savage CO, et al. Impairment of lung function, health status and functional capacity in patients with ANCAassociated vasculitis. Rheumatology (Oxford) 2005; 44: 623–628. 8 Schnabel A, Csernok E, Braun J, et al. Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegener’s granulomatosis. Am J Respir Crit Care Med 2000; 161: 399–405. 9 Hoffman GS, Sechler JM, Gallin JI, et al. Bronchoalveolar lavage analysis in Wegener’s granulomatosis. A method to study disease pathogenesis. Am Rev Respir Dis 1991; 143: 401–407. 10 Amitani R, Wilson R, Rutman A, et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol 1991; 4: 26–32. 11 Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 1997; 40: 2187–2198. 12 Wagner JG, Roth RA. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacol Rev 2000; 52: 349–374. 13 Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest 2007; 117: 549–556. 14 Perkins GD, Nathani N, McAuley DF, et al. In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury. Thorax 2007; 62: 36–42. 15 Torheim EA, Yndestad A, Bjerkeli V, et al. Increased expression of chemokines in patients with Wegener’s granulomatosis – modulating effects of methylprednisolone in vitro. Clin Exp Immunol 2005; 140: 376–383. 16 Ohta N, Fukase S, Aoyagi M. Serum levels of soluble adhesion molecules ICAM-1, VCAM-1 and E-selectin in patients with Wegener’s granulomatosis. Auris Nasus Larynx 2001; 28: 311–314. 17 Cockwell P, Brooks CJ, Adu D, et al. Interleukin-8: a pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int 1999; 55: 852–863. 18 Mukae H, Matsumoto N, Ashitani J, et al. Neutrophil-related cytokines and neutrophil products in bronchoalveolar lavage fluid of a patient with ANCA negative Wegener’s granulomatosis. Eur Respir J 1996; 9: 1950–1954. 19 Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187–192. 20 Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671–678. 21 Perkins GD, Chatterjie S, McAuley DF, et al. Role of nonbronchoscopic lavage for investigating alveolar inflammation and permeability in acute respiratory distress syndrome. Crit Care Med 2006; 34: 57–64. 22 Giudicelli J, Philip PJ, Delque P, et al. A single-step centrifugation method for separation of granulocytes and mononuclear cells from blood using discontinuous density gradient of Percoll. J Immunol Methods 1982; 54: 43–46. 23 Heit B, Kubes P. Measuring chemotaxis and chemokinesis: the under-agarose cell migration assay. Sci STKE 2003; 2003: L5. 24 Schnabel A, Reuter M, Gloeckner K, et al. Bronchoalveolar lavage cell profiles in Wegener’s granulomatosis. Respir Med 1999; 93: 498–506. 25 Schnabel A, Csernok E, Braun J, et al. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax 1999; 54: 771–778. 26 Jonker ND, Peters AM, Gaskin G, et al. A retrospective study of radiolabeled granulocyte kinetics in patients with systemic vasculitis. J Nucl Med 1992; 33: 491–497. 27 Cantin AM, North SL, Fells GA, et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987; 79: 1665–1673. 28 Cailes JB, O’Connor C, Pantelidis P, et al. Neutrophil activation in fibrosing alveolitis: a comparison of lone cryptogenic fibrosing alveolitis and systemic sclerosis. Eur Respir J 1996; 9: 992–999. 29 Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997; 89: 3503–3521. 30 Schmekel B, Karlsson SE, Linden M, et al. Myeloperoxidase in human lung lavage. I. A marker of local neutrophil activity. Inflammation 1990; 14: 447–454. 31 Kettritz R, Jennette JC, Falk RJ. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol 1997; 8: 386–394. 32 Lynch JP III, Standiford TJ, Rolfe MW, et al. Neutrophilic alveolitis in idiopathic pulmonary fibrosis. The role of interleukin-8. Am Rev Respir Dis 1992; 145: 1433–1439. 33 Miller EJ, Cohen AB, Nagao S, et al. Elevated levels of NAP-1/ interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis 1992; 146: 427–432. 34 Ralston DR, Marsh CB, Lowe MP, et al. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, a1-antitrypsin, and Fcc receptors. J Clin Invest 1997; 100: 1416–1424. 35 Csernok E, Ernst M, Schmitt W, et al. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994; 95: 244–250. 36 Zhou Z, Richard C, Menard HA. De novo synthesis of proteinase 3 by cytokine primed circulating human polymorphonuclear neutrophils and mononuclear cells. J Rheumatol 2000; 27: 2406–2411. 37 Loetscher P, Seitz M, Clark-Lewis I, et al. Both interleukin-8 receptors independently mediate chemotaxis. Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GRO-a and NAP-2. FEBS Lett 1994; 341: 187–192. 38 Hebert CA, Baker JB. Interleukin-8: a review. Cancer Invest 1993; 11: 743–750. 39 Liu L, Mul FP, Kuijpers TW, et al. Neutrophil transmigration across monolayers of endothelial cells and airway epithelial cells is regulated by differentmechanisms. Ann NY Acad Sci 1996; 796: 21–29. 40 Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 2002; 1: 19–25.|
Actions (login required)